Literature DB >> 23984849

Cardiac structure/function, protein expression, and DNA methylation are changed in adult female mice exposed to diethylstilbestrol in utero.

Rami Haddad1, Amanda Kasneci, Igal A Sebag, Lorraine E Chalifour.   

Abstract

The detrimental effects of in utero exposure to the non-steroidal estrogen diethylstilbestrol (DES) are particularly marked in women. Fetal hearts express estrogen receptors, making them potentially responsive to DES. To examine whether gestational exposure to DES would impact the heart, we exposed pregnant C57bl/6n dams to DES (0.1, 1.0, and 10.0 μg·(kg body mass)(-1)·day(-1)) on gestation days 11.5-14.5, and examined the measured cardiac structure/function and calcium homeostasis protein expression in adult females. At baseline, echocardiography revealed eccentric hypertrophy in mice treated with 10.0 μg·(kg body mass)(-1)·day(-1) DES, and immunoblots showed increased SERCA2a in all DES-treated mice. Mice were swim-trained to assess cardiac remodeling. Swim-trained vehicle-treated mice developed eccentric hypertrophy without changing SERCA2 or calsequestrin 2 expression. In contrast, no DES-treated mice hypertrophied, and all increased in SERCA2a and calsequestrin 2 expression after training. To determine whether DES-induced changes in DNA methylation is part of the mechanism for its long-term effects, we measured DNA methyltransferase expression and DNA methylation. Global DNA methylation and DNA methyltransferase 3a expression were unchanged. However, DES-treated mice had increased DNA methylation in the calsequestrin 2 promoter. Thus, gestational exposure to DES altered female ventricular DNA, cardiac structure/function, and calcium homeostasis protein expression. We conclude that gestational exposure to estrogenizing compounds may impact cardiac structure/function in adult females.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23984849     DOI: 10.1139/cjpp-2013-0014

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

Review 1.  Back to the future: transgenerational transmission of xenobiotic-induced epigenetic remodeling.

Authors:  Josep C Jiménez-Chillarón; Mark J Nijland; António A Ascensão; Vilma A Sardão; José Magalhães; Michael J Hitchler; Frederick E Domann; Paulo J Oliveira
Journal:  Epigenetics       Date:  2015-03-16       Impact factor: 4.528

Review 2.  Report of the National Heart, Lung, and Blood Institute Working Group on Sex Differences Research in Cardiovascular Disease: Scientific Questions and Challenges.

Authors:  Christine Maric-Bilkan; Arthur P Arnold; Doris A Taylor; Melinda Dwinell; Susan E Howlett; Nanette Wenger; Jane F Reckelhoff; Kathryn Sandberg; Gary Churchill; Ellis Levin; Martha S Lundberg
Journal:  Hypertension       Date:  2016-03-14       Impact factor: 10.190

3.  A Prospective Cohort Study of Prenatal Diethylstilbestrol Exposure and Cardiovascular Disease Risk.

Authors:  Rebecca Troisi; Linda Titus; Elizabeth E Hatch; Julie R Palmer; Dezheng Huo; William C Strohsnitter; Ervin Adam; Winnie Ricker; Marianne Hyer; Robert N Hoover
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

4.  Sex-specific cardiovascular responses to control or high fat diet feeding in C57bl/6 mice chronically exposed to bisphenol A.

Authors:  Bhavini B Patel; Mohamad Raad; Igal A Sebag; Lorraine E Chalifour
Journal:  Toxicol Rep       Date:  2015-10-01

5.  The cardiac calsequestrin gene transcription is modulated at the promoter by NFAT and MEF-2 transcription factors.

Authors:  Rafael Estrada-Avilés; Gabriela Rodríguez; Angel Zarain-Herzberg
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

Review 6.  Molecular pathways of oestrogen receptors and β-adrenergic receptors in cardiac cells: Recognition of their similarities, interactions and therapeutic value.

Authors:  J O Machuki; H Y Zhang; S E Harding; H Sun
Journal:  Acta Physiol (Oxf)       Date:  2017-10-30       Impact factor: 6.311

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.